Is Apogee Therapeutics (APGE) Fully Priced, Or Still A Bargain?

Apogee Therapeutics (APGE) has seen significant returns recently, but its valuation checks indicate it is currently expensive, scoring 1 out of 6 on Simply Wall St.'s valuation scale. The company's stock trades at a high price-to-book ratio compared to the biotech industry average, suggesting investors are paying a premium relative to its net assets. The article raises the question of whether the company can execute on its development plans strongly enough to justify its current rich valuation, or if its price will eventually align more closely with the broader biotech sector.